206 related articles for article (PubMed ID: 20233903)
1. The core circadian gene Cryptochrome 2 influences breast cancer risk, possibly by mediating hormone signaling.
Hoffman AE; Zheng T; Yi CH; Stevens RG; Ba Y; Zhang Y; Leaderer D; Holford T; Hansen J; Zhu Y
Cancer Prev Res (Phila); 2010 Apr; 3(4):539-48. PubMed ID: 20233903
[TBL] [Abstract][Full Text] [Related]
2. Clock-cancer connection in non-Hodgkin's lymphoma: a genetic association study and pathway analysis of the circadian gene cryptochrome 2.
Hoffman AE; Zheng T; Stevens RG; Ba Y; Zhang Y; Leaderer D; Yi C; Holford TR; Zhu Y
Cancer Res; 2009 Apr; 69(8):3605-13. PubMed ID: 19318546
[TBL] [Abstract][Full Text] [Related]
3. The circadian gene CRY2 is associated with breast cancer aggressiveness possibly via epigenomic modifications.
Mao Y; Fu A; Hoffman AE; Jacobs DI; Jin M; Chen K; Zhu Y
Tumour Biol; 2015 May; 36(5):3533-9. PubMed ID: 25740058
[TBL] [Abstract][Full Text] [Related]
4. Phenotypic effects of the circadian gene Cryptochrome 2 on cancer-related pathways.
Hoffman AE; Zheng T; Ba Y; Stevens RG; Yi CH; Leaderer D; Zhu Y
BMC Cancer; 2010 Mar; 10():110. PubMed ID: 20334671
[TBL] [Abstract][Full Text] [Related]
5. The role of polymorphisms in circadian pathway genes in breast tumorigenesis.
Dai H; Zhang L; Cao M; Song F; Zheng H; Zhu X; Wei Q; Zhang W; Chen K
Breast Cancer Res Treat; 2011 Jun; 127(2):531-40. PubMed ID: 20978934
[TBL] [Abstract][Full Text] [Related]
6. CLOCK in breast tumorigenesis: genetic, epigenetic, and transcriptional profiling analyses.
Hoffman AE; Yi CH; Zheng T; Stevens RG; Leaderer D; Zhang Y; Holford TR; Hansen J; Paulson J; Zhu Y
Cancer Res; 2010 Feb; 70(4):1459-68. PubMed ID: 20124474
[TBL] [Abstract][Full Text] [Related]
7. Circadian Gene Polymorphisms Associated with Breast Cancer Susceptibility.
Lesicka M; Jabłońska E; Wieczorek E; Pepłońska B; Gromadzińska J; Seroczyńska B; Kalinowski L; Skokowski J; Reszka E
Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31739444
[TBL] [Abstract][Full Text] [Related]
8. Common genetic polymorphisms of microRNA biogenesis pathway genes and risk of breast cancer: a case-control study in Korea.
Sung H; Lee KM; Choi JY; Han S; Lee JY; Li L; Park SK; Yoo KY; Noh DY; Ahn SH; Kang D
Breast Cancer Res Treat; 2011 Dec; 130(3):939-51. PubMed ID: 21766210
[TBL] [Abstract][Full Text] [Related]
9. CRY2 is suppressed by FOXM1 mediated promoter hypermethylation in breast cancer.
Liu L; Shen H; Wang Y
Biochem Biophys Res Commun; 2017 Aug; 490(1):44-50. PubMed ID: 28579430
[TBL] [Abstract][Full Text] [Related]
10. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
[TBL] [Abstract][Full Text] [Related]
11. Breast cancer risk associated with genotypic polymorphism of the genes involved in the estrogen-receptor-signaling pathway: a multigenic study on cancer susceptibility.
Yu JC; Hsu HM; Chen ST; Hsu GC; Huang CS; Hou MF; Fu YP; Cheng TC; Wu PE; Shen CY
J Biomed Sci; 2006 May; 13(3):419-32. PubMed ID: 16502042
[TBL] [Abstract][Full Text] [Related]
12. Risk of estrogen receptor-positive and -negative breast cancer and single-nucleotide polymorphism 2q35-rs13387042.
Milne RL; Benítez J; Nevanlinna H; Heikkinen T; Aittomäki K; Blomqvist C; Arias JI; Zamora MP; Burwinkel B; Bartram CR; Meindl A; Schmutzler RK; Cox A; Brock I; Elliott G; Reed MW; Southey MC; Smith L; Spurdle AB; Hopper JL; Couch FJ; Olson JE; Wang X; Fredericksen Z; Schürmann P; Bremer M; Hillemanns P; Dörk T; Devilee P; van Asperen CJ; Tollenaar RA; Seynaeve C; Hall P; Czene K; Liu J; Li Y; Ahmed S; Dunning AM; Maranian M; Pharoah PD; Chenevix-Trench G; Beesley J; ; ; Bogdanova NV; Antonenkova NN; Zalutsky IV; Anton-Culver H; Ziogas A; Brauch H; Justenhoven C; Ko YD; Haas S; Fasching PA; Strick R; Ekici AB; Beckmann MW; Giles GG; Severi G; Baglietto L; English DR; Fletcher O; Johnson N; dos Santos Silva I; Peto J; Turnbull C; Hines S; Renwick A; Rahman N; Nordestgaard BG; Bojesen SE; Flyger H; Kang D; Yoo KY; Noh DY; Mannermaa A; Kataja V; Kosma VM; García-Closas M; Chanock S; Lissowska J; Brinton LA; Chang-Claude J; Wang-Gohrke S; Shen CY; Wang HC; Yu JC; Chen ST; Bermisheva M; Nikolaeva T; Khusnutdinova E; Humphreys MK; Morrison J; Platte R; Easton DF;
J Natl Cancer Inst; 2009 Jul; 101(14):1012-8. PubMed ID: 19567422
[TBL] [Abstract][Full Text] [Related]
13. NRF1 motif sequence-enriched genes involved in ER/PR -ve HER2 +ve breast cancer signaling pathways.
Ramos J; Das J; Felty Q; Yoo C; Poppiti R; Murrell D; Foster PJ; Roy D
Breast Cancer Res Treat; 2018 Nov; 172(2):469-485. PubMed ID: 30128822
[TBL] [Abstract][Full Text] [Related]
14. Genetic susceptibility loci for subtypes of breast cancer in an African American population.
Palmer JR; Ruiz-Narvaez EA; Rotimi CN; Cupples LA; Cozier YC; Adams-Campbell LL; Rosenberg L
Cancer Epidemiol Biomarkers Prev; 2013 Jan; 22(1):127-34. PubMed ID: 23136140
[TBL] [Abstract][Full Text] [Related]
15. Confirmation of 5p12 as a susceptibility locus for progesterone-receptor-positive, lower grade breast cancer.
Milne RL; Goode EL; García-Closas M; Couch FJ; Severi G; Hein R; Fredericksen Z; Malats N; Zamora MP; Arias Pérez JI; Benítez J; Dörk T; Schürmann P; Karstens JH; Hillemanns P; Cox A; Brock IW; Elliot G; Cross SS; Seal S; Turnbull C; Renwick A; Rahman N; Shen CY; Yu JC; Huang CS; Hou MF; Nordestgaard BG; Bojesen SE; Lanng C; Grenaker Alnæs G; Kristensen V; Børrensen-Dale AL; Hopper JL; Dite GS; Apicella C; Southey MC; Lambrechts D; Yesilyurt BT; Floris G; Leunen K; Sangrajrang S; Gaborieau V; Brennan P; McKay J; Chang-Claude J; Wang-Gohrke S; Radice P; Peterlongo P; Manoukian S; Barile M; Giles GG; Baglietto L; John EM; Miron A; Chanock SJ; Lissowska J; Sherman ME; Figueroa JD; Bogdanova NV; Antonenkova NN; Zalutsky IV; Rogov YI; Fasching PA; Bayer CM; Ekici AB; Beckmann MW; Brenner H; Müller H; Arndt V; Stegmaier C; Andrulis IL; Knight JA; Glendon G; Mulligan AM; Mannermaa A; Kataja V; Kosma VM; Hartikainen JM; Meindl A; Heil J; Bartram CR; Schmutzler RK; Thomas GD; Hoover RN; Fletcher O; Gibson LJ; dos Santos Silva I; Peto J; Nickels S; Flesch-Janys D; Anton-Culver H; Ziogas A; Sawyer E; Tomlinson I; Kerin M; Miller N; Schmidt MK; Broeks A; Van 't Veer LJ; Tollenaar RA; Pharoah PD; Dunning AM; Pooley KA; Marme F; Schneeweiss A; Sohn C; Burwinkel B; Jakubowska A; Lubinski J; Jaworska K; Durda K; Kang D; Yoo KY; Noh DY; Ahn SH; Hunter DJ; Hankinson SE; Kraft P; Lindstrom S; Chen X; Beesley J; Hamann U; Harth V; Justenhoven C; ; Winqvist R; Pylkäs K; Jukkola-Vuorinen A; Grip M; Hooning M; Hollestelle A; Oldenburg RA; Tilanus-Linthorst M; Khusnutdinova E; Bermisheva M; Prokofieva D; Farahtdinova A; Olson JE; Wang X; Humphreys MK; Wang Q; Chenevix-Trench G; ; ; Easton DF
Cancer Epidemiol Biomarkers Prev; 2011 Oct; 20(10):2222-31. PubMed ID: 21795498
[TBL] [Abstract][Full Text] [Related]
16. Hypermethylation pattern of ESR and PgR genes and lacking estrogen and progesterone receptors in human breast cancer tumors: ER/PR subtypes.
Pirouzpanah S; Taleban FA; Mehdipour P; Sabour S; Atri M
Cancer Biomark; 2018 Feb; 21(3):621-638. PubMed ID: 29278880
[TBL] [Abstract][Full Text] [Related]
17. Differential expression of progesterone receptor, FOXA1, GATA3, and p53 between pre- and postmenopausal women with estrogen receptor-positive breast cancer.
Hosoda M; Yamamoto M; Nakano K; Hatanaka KC; Takakuwa E; Hatanaka Y; Matsuno Y; Yamashita H
Breast Cancer Res Treat; 2014 Apr; 144(2):249-61. PubMed ID: 24549642
[TBL] [Abstract][Full Text] [Related]
18. Germ-line mutations in BRCA1 or BRCA2 in the normal breast are associated with altered expression of estrogen-responsive proteins and the predominance of progesterone receptor A.
Mote PA; Leary JA; Avery KA; Sandelin K; Chenevix-Trench G; Kirk JA; Clarke CL;
Genes Chromosomes Cancer; 2004 Mar; 39(3):236-48. PubMed ID: 14732925
[TBL] [Abstract][Full Text] [Related]
19. Association between family history of cancer and breast cancer defined by estrogen and progesterone receptor status.
Tutera AM; Sellers TA; Potter JD; Drinkard CR; Wiesner GL; Folsom AR
Genet Epidemiol; 1996; 13(2):207-21. PubMed ID: 8722747
[TBL] [Abstract][Full Text] [Related]
20. Replication of five GWAS-identified loci and breast cancer risk among Hispanic and non-Hispanic white women living in the Southwestern United States.
Slattery ML; Baumgartner KB; Giuliano AR; Byers T; Herrick JS; Wolff RK
Breast Cancer Res Treat; 2011 Sep; 129(2):531-9. PubMed ID: 21475998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
